Table 4.
Summary of FDA-approved novel agents for PTCL.
| Agent | Patients (n) | Histology | Dose/schedule | ORR/CR % | DOR (months) | SCT* (n) |
|---|---|---|---|---|---|---|
| Pralatrexate | 109 | All PTCL | 30 mg/m2 IV Weekly 6/7 weeks |
29/11 | 10.1 | 6 |
| Romidepsin | 131 | All PTCL | 14 mg/ m2 IV Weekly 3/4 weeks |
25/15 | 17 | 6 |
| B-vedotin | 58 | ALCL* | 1.8 mg/kg IV Every 3 weeks |
86/57 | 12.6 | 11 |
*
Patients proceeding to autologous or allogeneic SCT after achieving response with single agent therapy.
ALCL, anaplastic large cell lymphoma; CR, complete response; DOR, duration of response; FDA, US Food and Drug Administration; IV, intravenously; ORR, objective response rate; SCT, stem-cell transplantation; PTCL-U, peripheral T-cell lymphoma.